Globus Medical (GMED)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $9.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Globus Medical (GMED) Financials: Revenue, Profit and Cash Flow
Globus Medical reported revenue of $2.94B for the fiscal year ended Dec 31, 2025, up 16.7% from the year before. That year, net income was $537.87M with a net margin of 18.3%, operating cash flow was $753.45M and free cash flow was $588.77M. The quarter ended Sep 30, 2026 had revenue of $763.72M and net income of $141.17M.
Revenue and Margins
The operating margin was 16.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $563.99M, a compound annual rate of 20.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.94B | +16.7% | 67.4% | 16.3% | 18.3% |
| Dec 2024 | $2.52B | +60.6% | 58.9% | 6.6% | 4.1% |
| Dec 2023 | $1.57B | +53.3% | 65.1% | 8.5% | 7.8% |
| Dec 2022 | $1.02B | +6.8% | 74.2% | 22.3% | 18.6% |
| Dec 2021 | $958.10M | +21.4% | 75.0% | 17.9% | 15.6% |
| Dec 2020 | $789.04M | +0.5% | 72.4% | 14.1% | 13.0% |
| Dec 2019 | $785.37M | +10.2% | 77.1% | 21.9% | 19.8% |
| Dec 2018 | $712.97M | +12.1% | 77.6% | 23.7% | 21.9% |
| Dec 2017 | $635.98M | +12.8% | 76.3% | 25.4% | 16.9% |
| Dec 2016 | $563.99M | N/A | 76.1% | 27.3% | 18.5% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 422.3% from the year before. In the quarter ended Sep 2026, net income rose 18.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.94B | $2.52B | $1.57B | $1.02B | $958.10M | $789.04M | $785.37M | $712.97M | $635.98M | $563.99M |
| Cost of revenue | $957.80M | $1.04B | $548.17M | $263.73M | $239.22M | $217.46M | $179.97M | $159.41M | $150.45M | $134.71M |
| Gross profit | $1.98B | $1.48B | $1.02B | $759.12M | $718.88M | $571.58M | $605.39M | $553.56M | $485.52M | $429.29M |
| Research and development | $147.25M | $163.75M | $124.01M | $73.02M | $97.35M | $84.52M | $60.07M | $55.50M | $43.68M | $44.53M |
| Operating income | $479.82M | $165.99M | $133.14M | $227.95M | $171.95M | $111.43M | $171.99M | $169.32M | $161.84M | $154.14M |
| Net income | $537.87M | $102.98M | $122.87M | $190.17M | $149.19M | $102.28M | $155.21M | $156.47M | $107.35M | $104.34M |
| EBITDA | $900.88M | $620.35M | $370.62M | $302.43M | $243.76M | $175.41M | $224.19M | $218.63M | $208.06M | $197.06M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $763.72M | $789.61M | $759.85M | $826.42M | $769.05M | $745.34M | $598.12M | $657.29M | $625.71M | $629.69M | $606.67M | $616.53M |
| Gross profit | $530.80M | $548.17M | $525.79M | $565.31M | $516.51M | $496.58M | $402.72M | $393.86M | $355.19M | $369.65M | $365.18M | $351.05M |
| Operating income | $177.55M | $182.43M | $150.39M | $169.34M | $137.36M | $76.11M | $97.00M | $60.27M | $48.10M | $49.62M | $8.00M | $10.12M |
| Net income | $141.17M | $151.57M | $124.30M | $140.59M | $118.97M | $202.85M | $75.46M | $26.50M | $51.84M | $31.76M | -$7.12M | $15.03M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $14.74M by $511.42M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.30B | $5.25B | $5.09B | $2.08B | $1.96B | $1.68B | $1.53B | $1.30B | $1.08B | $927.64M |
| Current assets | $2.13B | $2.18B | $1.92B | $983.34M | $864.52M | $821.76M | $687.47M | $630.68M | $620.34M | $513.77M |
| Cash and equivalents | $526.16M | $784.44M | $467.29M | $150.47M | $193.07M | $239.40M | $195.72M | $139.75M | $118.82M | $66.95M |
| Total liabilities | $729.51M | $1.07B | $1.09B | $229.75M | $215.88M | $173.19M | $129.63M | $115.15M | $110.72M | $95.56M |
| Short-term debt | $14.74M | $443.35M | $0 | $2.54M | $94.41M | $88.69M | $74.66M | $4.51M | N/A | N/A |
| Long-term debt | N/A | N/A | $417.40M | $0 | N/A | N/A | N/A | N/A | $0 | $0 |
| Shareholder equity | $4.57B | $4.18B | $4.00B | $1.85B | $1.74B | $1.51B | $1.40B | $1.19B | $967.78M | $832.08M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.53B | $5.49B | $5.44B | $5.30B | $5.10B | $4.96B | $4.71B | $5.25B | $5.09B | $4.99B | $4.94B | $5.09B |
| Total liabilities | $731.94M | $719.65M | $707.24M | $729.51M | $696.82M | $665.41M | $623.08M | $1.07B | $1.02B | $1.02B | $1.02B | $1.09B |
| Cash and equivalents | $441.27M | $507.75M | $560.95M | $526.16M | $371.77M | $229.45M | $461.27M | $784.44M | $622.77M | $410.42M | $354.06M | $467.29M |
| Shareholder equity | $4.80B | $4.77B | $4.73B | $4.57B | $4.40B | $4.30B | $4.09B | $4.18B | $4.07B | $3.98B | $3.92B | $4.00B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 78.1% of operating cash flow. Share repurchases came to 51.0% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $753.45M | $520.64M | $243.50M | $178.47M | $276.27M | $198.79M | $171.97M | $181.64M | $159.06M | $147.82M |
| Capital expenditures | $164.68M | $115.43M | $78.27M | $74.05M | $56.90M | $63.66M | $70.75M | $59.70M | $51.30M | $40.91M |
| Free cash flow | $588.77M | $405.21M | $165.22M | $104.42M | $219.38M | $135.13M | $101.22M | $121.95M | $107.75M | $106.91M |
| Share repurchases | $300.45M | $85.79M | $225.56M | $144.49M | $0 | $104.67M | $0 | $0 | N/A | N/A |
| Investing cash flow | -$355.01M | -$176.05M | $302.97M | -$110.36M | -$375.94M | -$117.32M | -$140.28M | -$193.03M | -$111.28M | -$162.74M |
| Financing cash flow | -$679.16M | -$27.70M | -$231.82M | -$109.96M | $54.15M | -$38.66M | $24.44M | $32.57M | $1.63M | $470.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $265.23M | $209.74M | $202.36M | $248.59M | $249.69M | $77.86M | $177.30M | $210.34M | $203.65M | $54.26M | $52.39M | $104.67M |
| Capital expenditures | $40.39M | $33.17M | $39.62M | $46.20M | $35.82M | $46.56M | $36.10M | $17.11M | $41.95M | $27.80M | $28.57M | $22.88M |
| Free cash flow | $224.84M | $176.57M | $162.75M | $202.39M | $213.88M | $31.30M | $141.20M | $193.23M | $161.70M | $26.46M | $23.82M | $81.79M |
Frequently Asked Questions About GMED
What is Globus Medical's annual revenue?
Globus Medical reported revenue of $2.94B for the fiscal year ended Dec 31, 2025.
How fast is Globus Medical's revenue growing?
Revenue was up 16.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 42.2%.
Is Globus Medical profitable?
Yes. Globus Medical reported net income of $537.87M for the fiscal year ended Dec 31, 2025, with a net margin of 18.3%.
How much free cash flow does GMED generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $753.45M minus capital expenditures of $164.68M produced free cash flow of $588.77M.
How much debt does Globus Medical have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $14.74M and cash and equivalents of $526.16M.
GMED pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts